These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 15718335)

  • 21. [Not Available].
    Aktuelle Urol; 2015 Sep; 46(5):356-7. PubMed ID: 26394083
    [No Abstract]   [Full Text] [Related]  

  • 22. Editorial comment on: prognosis of Japanese metastatic renal cell carcinoma patients in the cytokine era: a cooperative group report of 1463 patients.
    Ohlmann CH
    Eur Urol; 2010 Feb; 57(2):325-6. PubMed ID: 19136198
    [No Abstract]   [Full Text] [Related]  

  • 23. A phase II study of irinotecan in patients with advanced renal cell carcinoma.
    Fizazi K; Rolland F; Chevreau C; Droz JP; Mery-Mignard D; Culine S; Escudier B
    Cancer; 2003 Jul; 98(1):61-5. PubMed ID: 12833456
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [A case of gastric carcinosarcoma treated with surgical resection and irinotecan and mitomycin C combination therapy].
    Miyakawa A; Ishibashi H; Takashina A; Ishigaki K; Iwai Y; Abe H; Katagiri T; Sakaguchi Y; Matsushima T; Tamura T; Komata S; Kubota M; Suzuki Y; Nakamura A; Itobayashi E; Shimura H; Shimura K
    Nihon Shokakibyo Gakkai Zasshi; 2014 Jan; 111(1):105-14. PubMed ID: 24390265
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rationale for mitomycin and irinotecan use in advanced breast cancer.
    Xu Y; Shapiro CL
    Oncology (Williston Park); 2003 May; 17(5 Suppl 5):25-8. PubMed ID: 12800602
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [ASCO 2006: temsirolimus increases survival].
    Aktuelle Urol; 2006 Sep; 37(5 Suppl):12. PubMed ID: 23646393
    [No Abstract]   [Full Text] [Related]  

  • 27. Individualized chemotherapeutic regimen for each histological subtype of ovarian carcinoma.
    Shimizu Y
    Gan To Kagaku Ryoho; 1997 May; 24 Suppl 1():61-9. PubMed ID: 9210889
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mitomycin as a modulator of irinotecan anticancer activity.
    Villalona-Calero MA; Kolesar JM
    Oncology (Williston Park); 2002 Aug; 16(8 Suppl 7):21-5. PubMed ID: 12199629
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Irinotecan and cisplatin in advanced gastric or gastroesophageal junction carcinoma.
    Ajani JA; Fairweather J; Pisters PW; Charnsangavej C
    Oncology (Williston Park); 2000 Dec; 14(12 Suppl 14):19-21. PubMed ID: 11200143
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chemoimmunotherapy of metastatic renal cell carcinoma.
    Bukowski RM
    Cancer Invest; 1999; 17(6):460-1. PubMed ID: 10434957
    [No Abstract]   [Full Text] [Related]  

  • 31. [Circumvention of the multidrug-resistance in renal cancer by bisbenzylisoquinoline].
    Kakehi Y; Hashimura T; Yoshida O; Segawa T; Kanematsu A
    Hinyokika Kiyo; 1993 Dec; 39(12):1227-32. PubMed ID: 8285174
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Irinotecan (CPT-11) combined with cisplatin for small cell carcinoma of the nasal cavity.
    Hakuba N; Hyodo M; Yokoi T; Sato H
    Auris Nasus Larynx; 2006 Mar; 33(1):67-70. PubMed ID: 16168589
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Chemotherapy of irinotecan (CPT-11) combined with cisplatin in patients with advanced gastric cancer].
    Sato A; Shimada K; Nakamachi M; Wada M; Koda T; Matsukawa M
    Nihon Rinsho; 2001 Apr; 59 Suppl 4():375-80. PubMed ID: 11424409
    [No Abstract]   [Full Text] [Related]  

  • 34. Second-line therapy for refractory renal-cell carcinoma.
    Zustovich F; Lombardi G; Nicoletto O; Pastorelli D
    Crit Rev Oncol Hematol; 2012 Jul; 83(1):112-22. PubMed ID: 21944739
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [First-line therapy for German patients with metastatic kidney neoplasms in EORTC-Protocol 30012].
    Rexer H
    Urologe A; 2004 Aug; 43(8):992-3. PubMed ID: 15316609
    [No Abstract]   [Full Text] [Related]  

  • 36. Cytokines in combination with chemotherapy for advanced renal carcinoma--the importance of patient selection.
    Joffe JK; Patel PM; Banks RE; Selby PJ
    Cancer Biother Radiopharm; 1996 Oct; 11(5):309-13. PubMed ID: 10851510
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Advances in chemotherapy for renal cell carcinoma.
    Huben RP
    Semin Urol; 1992 Feb; 10(1):16-22. PubMed ID: 1565899
    [No Abstract]   [Full Text] [Related]  

  • 38. Establishment of the standard regimen for non-small-cell lung cancer in Japan.
    Masuda N
    Oncology (Williston Park); 2001 Jan; 15(1 Suppl 1):13-8. PubMed ID: 11221016
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of recurrent or metastatic renal cell carcinoma.
    Shah RN; Ahmad T; Eisen TG
    Expert Rev Anticancer Ther; 2004 Dec; 4(6):1069-80. PubMed ID: 15606334
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Metastasized renal cell carcinoma - research subjects needed!].
    Aktuelle Urol; 2014 Mar; 45(2):99. PubMed ID: 24700063
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.